Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emily Hayes

San Francisco, CA
Emily Hayes is a writer/editor with over 20 years’ experience in medical journalism, including magazines for specialist clinicians, government health publications, business newswires and pharma trade press.  Her educational background lies in journalism and political science. Emily has dual citizenship and has experience working in the UK and US. Since 2008, she has been a senior writer on staff with “The Pink Sheet,” working out of her home base in biopharma hub San Francisco. She enjoys covering drug development, with special areas of focus in cancer, particularly immunotherapy, and cardiology/metabolics. She covers major scientific meetings regularly, including the American Society of Clinical Oncology, and appreciates interactions with key opinion leaders while interpreting drug trial results. In her free time, she is a professional jazz/blues/country vocalist.
Advertisement
Set Alert for Articles By Emily Hayes

Latest From Emily Hayes

Ultragenyx Gets Commercial Feet Wet With Mepsevii Launch In Sly Syndrome

Commercial opportunity for Mepsevii is small, but launch paves way for company's second product burosumab, following on its heels.

Launches Commercial

Acorda's Parkinson's Drug Tozadenant May Not Survive Safety Setback

The safety problems reported for tozadenant – including deaths – have not been reported for other A2a receptor inhibitors and the company sees them as "idiosyncratic," stirring doubts about a commercial future.

Drug Safety Neurology

PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride

Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.

Market Intelligence ImmunoOncology

Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

ImmunoOncology Cancer

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

ImmunoOncology Clinical Trials

Five Prime Bounces Back With Good Spin On Cabiralizumab Data

Bristol's new Phase I study of Opdivo with Five Prime's cabiralizumab in second-line pancreatic cancer restored faith in the combo for some investors, as did a full presentation of pancreatic cancer data slated for SITC.

Cancer ImmunoOncology
See All
Advertisement
UsernamePublicRestriction

Register